MeSH tree: D02.145.150.500
Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The findings suggest that ...
Aug 6, 2025
0
11
Scientists studying a hard-to-treat form of blood cancer called acute myeloid leukemia (AML) have found that a type of treatment—immunotherapy—may help change the environment where cancer cells live, possibly helping the ...
Jul 29, 2025
0
20
Even treated with the most advanced therapies, patients with glioblastoma—an aggressive brain cancer—typically survive less than two years after diagnosis. Efforts to treat this cancer with the latest immunotherapies have ...
Nov 7, 2024
0
36
A team from the Wistar Institute has demonstrated the role of Parkin—a protein implicated in Parkinson's disease—in the body's innate immune response to cancer. Parkin is not expressed in several cancers.
Sep 18, 2024
0
45
A new study led by researchers at Beth Israel Deaconess Medical Center (BIDMC) and Boston Children's Hospital and published in Nature Immunology shows how tumors grow by avoiding the immune system.
Aug 26, 2024
0
130
A new research paper titled "Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy" has been published in Oncotarget.
Jun 5, 2024
0
18
Researchers at Hackensack Meridian's John Theurer Cancer Center (JTCC), are part of a published Phase 3 study reporting on the equivalent safety and effectiveness in the oral treatment of blood cancers–such as myelodysplastic ...
Jan 31, 2024
0
39
Endocrine resistance—a major cause of breast cancer deaths—can be underpinned by an epigenetic change called DNA methylation, researchers at the Garvan Institute of Medical Research have discovered. The team successfully ...
Jan 9, 2024
0
39
Some patients with myelodysplastic syndromes, like acute myeloid leukemia, benefit from a chemotherapy drug called decitabine that stunts cancer growth. But many others are resistant to decatibine's effects or become resistant ...
Nov 16, 2023
0
41
Epigenetic changes can cause prostate cancer to resist treatment by switching genes on or off. One epigenetic mechanism tags genes with DNA methylation marks. This process is mediated by molecules called DNA methyltransferases. ...
Nov 15, 2023
0
37
